Overview of Cellular Immunotherapy for Patients with Glioblastoma
High grade gliomas (HGG) including glioblastomas (GBM) are the most common and devastating primary brain tumours. Despite important progresses in GBM treatment that currently includes surgery combined to radio- and chemotherapy, GBM patients' prognosis remains very poor. Immunotherapy is one of...
Saved in:
| Main Authors: | Elodie Vauleon, Tony Avril, Brigitte Collet, Jean Mosser, Véronique Quillien |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2010/689171 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dual IRE1 RNase functions dictate glioblastoma development
by: Stéphanie Lhomond, et al.
Published: (2018-01-01) -
SPECIFIC IMMUNOTHERAPY AND CELLULAR IMMUNITY IN PATIENTS WITH CERVICAL CANCER
by: D. K. Kenbaeva, et al.
Published: (2014-07-01) -
Measles Virus as a Vector Platform for Glioblastoma Immunotherapy (Review)
by: E. Yu. Nikolaeva, et al.
Published: (2022-02-01) -
Glioblastoma multiforme: an updated overview of temozolomide resistance mechanisms and strategies to overcome resistance
by: Jianlin Pu, et al.
Published: (2025-05-01) -
Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia
by: Juwita Werner, et al.
Published: (2025-04-01)